^ Top

drsuhail@yahoo.com

Call: +923-111-11-66-00

Menu

Blog

Shining a Light on Glaucoma: Understanding Selective Laser Trabeculoplasty (SLT)

Glaucoma, a condition that can silently steal your vision, is a major global health concern. Managing intraocular pressure (IOP) is key to slowing its progression, and while eye drops have long been a mainstay, a modern approach called Selective Laser Trabeculoplasty (SLT) is gaining significant traction. Let's delve into what makes SLT a noteworthy option in the fight against glaucoma.

How Does SLT Work and How Effective Is It?

SLT is an outpatient procedure that uses targeted laser energy to stimulate the trabecular meshwork, the eye's natural drainage system, to improve the outflow of aqueous humor and thereby lower IOP. Numerous studies have explored its effectiveness, often comparing it to traditional treatments like Argon Laser Trabeculoplasty (ALT) and IOP-lowering medications.

Research indicates that SLT can be at least as effective as ALT in reducing IOP, and in some cases, may even provide a more pronounced IOP decrease after a few months. Importantly, SLT appears to have fewer adverse events compared to ALT. Furthermore, SLT has demonstrated its ability to reduce the number of IOP-lowering medications needed by patients. Some studies even suggest that a significant proportion of patients can remain medication-free for a considerable period after primary SLT treatment.

A Safe Procedure?

The safety profile of SLT appears to be good, with studies reporting no vision-threatening intra- or post-procedural complications. While some transient issues like corneal edema or subepithelial haze have been observed in rare cases after bilateral SLT, the overall consensus suggests it's a well-tolerated procedure. Notably, when compared to Micropulse Laser Trabeculoplasty (MLT), SLT may be associated with a higher rate of postoperative IOP spikes in the short term, although long-term IOP reduction and failure rates might be similar.

SLT Across Different Types of Glaucoma

The utility of SLT extends beyond just primary open-angle glaucoma (POAG). Studies are exploring its effectiveness in various glaucoma subtypes, including normal-tension glaucoma (NTG), where it has shown potential as both a first-line and second-line treatment in lowering IOP. Even in uveitic glaucoma, which can be more complex to manage, SLT has demonstrated efficacy in patients with glaucoma refractory to medical treatment, though careful monitoring is crucial. Preliminary research also suggests that a variation called direct selective laser trabeculoplasty (DSLT) might be a useful and safe procedure for managing IOP and reducing medication needs in both POAG and primary angle-closure glaucoma (PACG). However, in cases of angle-recession glaucoma (ARG), patients might have a higher likelihood of inadequate IOP reduction post-SLT.

Predicting SLT Success

Understanding what factors influence the effectiveness of SLT is crucial for optimizing patient selection and managing expectations. Research suggests that baseline trabecular outflow facilities might be the strongest predictor of SLT effectiveness. Interestingly, pre-SLT medical treatment that enhances uveoscleral or trabecular outflow might potentially compromise the percentage IOP reduction achieved by subsequent SLT. Additionally, the intraocular pressure before SLT can significantly impact the duration until a subsequent pressure-reducing intervention is needed in patients who have previously undergone glaucoma treatment.

The Economic Advantage

Beyond its clinical benefits, SLT also presents a compelling economic case. Studies evaluating the economic impact of initial glaucoma treatments suggest that SLT can have a significantly lower economic impact compared to continuous eye drop instillation over both short and long-term periods. This makes SLT not only a beneficial treatment for patients but also a potentially cost-effective option for healthcare systems.

Expanding Access: The Role of Optometrists

Traditionally performed by ophthalmologists, the delivery of SLT is evolving. Research from the UK indicates that outcomes of SLT treatment delivered by optometrists are comparable to those delivered by ophthalmologists up to 24 months post-treatment. This suggests that appropriately trained optometrists can play a vital role in expanding access to this valuable treatment. However, a study in Saudi Arabia found that despite good overall acceptance of SLT as a first-line treatment, most ophthalmologists still primarily use medical therapy, with inadequate training being cited as a major barrier to wider adoption of SLT as initial therapy.

The Future of SLT

SLT has firmly established itself as a valuable tool in the management of glaucoma. Its efficacy in lowering IOP and reducing medication burden, coupled with its favorable safety profile and potential economic benefits, make it an increasingly attractive option. Ongoing research continues to refine our understanding of its long-term effects, its application in diverse glaucoma subtypes, and the factors that contribute to its success, paving the way for even more tailored and effective glaucoma care.

References

  1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-2090.
  2. Schmidl D, Hommer N, Hommer A. An Exploratory Retrospective Data Analysis Comparing the Outcomes of Selective Laser Trabeculoplasty and Argon Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension in Vienna, Austria, from the Year 2012 to 2022. Medicina (Kaunas). 2023;59(12):2075.
  3. Church B, Wassermann P. Real-world results of the Zeiss selective laser trabeculoplasty in adult South African primary open-angle glaucoma patients. Ther Adv Ophthalmol. 2024;16:25158414241302891.
  4. Nijs J, Vandewalle E, Stalmans I, Lemmens S. Acute corneal edema and residual subepithelial haze after bilateral selective laser trabeculoplasty: A case series. Saudi J Ophthalmol. 2024;38(4):396-400.
  5. Zhu D, Shah PP, Zhang C, et al. Outcomes of Micropulse Laser Trabeculoplasty Compared to Selective Laser Trabeculoplasty: A Systematic Review and Meta-Analysis. Clin Ophthalmol. 2024;18:2205-2215.
  6. Alwazae M, Aljasim LA, Alhumud A, Alsarhan S. Acceptance of Selective Laser Trabeculoplasty as a First-Line Treatment for Glaucoma Among Saudi Ophthalmologists. Cureus. 2024;16(1):e52360.
  7. Dendumrongsup W. Identifying Baseline Predictors of Selective Laser Trabeculoplasty Effectiveness: An Alternative Mathematical Approach. Cureus. 2024;16(2):e54116.
  8. Thelen P, Böhringer D, Keye P, Reinhard T, Lübke J. Selective Laser Trabeculoplasty after a Previous Glaucoma Treatment. Biomedicines. 2024;12(10):2212.
  9. Nitta K, Sugihara K, Narita A, et al. Efficacy and safety of first-line or second-line selective laser trabeculoplasty for normal-tension glaucoma: a multicentre cohort study. BMJ Open Ophthalmol. 2024;9(1):e001563.
  10. Suzuki Y, Takagi M, Nitta K, et al. Efficacy and safety of selective laser trabeculoplasty for uveitic glaucoma: a retrospective case series. BMC Ophthalmol. 2025;25(1):33.
  11. Lanza M, Schiano Lomoriello S, Bonfrate R, et al. First results of direct selective laser trabeculoplasty in primary open-angle glaucoma and primary angle closure glaucoma: a 1 year follow-up. BMJ Open Ophthalmol. 2025;10(1):e001875.
  12. Dossantos J, Muser T, Hill D, et al. Intraocular Pressure Response in the Untreated Contralateral Eye After Selective Laser Trabeculoplasty. Cureus. 2024;16(8):e67537.
  13. Dossantos J, Akosman S, Hill D, Mishra S, Thomasian J, Lesche S, Belyea D. The Effects of Selective Laser Trabeculoplasty in Patients With Angle Recession Glaucoma. Cureus. 2024;16(11):e73749.
  14. Konstantakopoulou E, McHugh J, ????? S, et al. Optometrist-delivered selective laser trabeculoplasty: design and delivery of a national training programme. Eye (Lond). 2024.
  15. Lee CN, Delaney A, Richardson JAL, et al. Comparative outcomes of selective laser trabeculoplasty delivered by optometrists compared with ophthalmologists: a UK-based multicentre observational study. BMJ Open Ophthalmology. 2024;9(1):e001870.
  16. Narayanaswamy A, Sood SR, Thakur S. Selective laser trabeculoplasty: An updated narrative review. Indian J Ophthalmol. 2024;72(3):313-321.
  17. Pillunat KR, Kohen L, Kretz FTA, et al. Effectiveness and safety of VISULAS® green selective laser trabeculoplasty: 12-month results of a prospective, interventional, multi-center clinical investigation. Int Ophthalmol. 2024;44(1):147-156.
  18. Gad AAM, Hassan BHA, Gamal AF, Elsayed AMM. Selective laser trabeculoplasty for treatment of primary open angle glaucoma in Egyptian patients: A prospective study. BMC Ophthalmol. 2025;25(1):61.
  19. Konstantakopoulou E, Gazzard G, Garway-Heath DF, et al. Effect of Selective Laser Trabeculoplasty vs Eye Drops for First-line Treatment of Open-Angle Glaucoma: The LiGHT Trial. JAMA Ophthalmol. 2025;143(3):235-243.
  20. Maltsev DS, Kulikov AN, Kazak AA. Iris Microcirculation After Selective Laser Trabeculoplasty: A Pilot Optical Coherence Tomography Angiography Study. Vision (Basel). 2025;9(1):21.
  21. Takagi M, Nitta K, Sugihara K, et al. Effect of first-line and second-line selective laser trabeculoplasty on corneal hysteresis in normal-tension glaucoma: a 24-month prospective study. BMC Ophthalmol. 2025;25(1):76.
  22. Tavares IM, de Moraes HV Jr, Gomes JAP, Susanna R Jr. Economic impact of initial glaucoma treatment with selective laser trabeculoplasty versus eye drops in the Brazilian Public Health System. Arq Bras Oftalmol. 2025;88(1):e20240142.
  23. Hirabayashi M, Mellencamp E, Duong S, et al. Effect of Selective Laser Trabeculoplasty on the Fellow Eye. J Curr Glaucoma Pract. 2023;17(4):175-177.
  24. Atanasovska Velkovska M, Gori?ar K, Blagus T, Dolžan V, Cvenkel B. Association of Matrix Metalloproteinases Polymorphisms with Glaucoma Risk, Glaucoma Phenotype, and Response to Treatment with Selective Laser Trabeculoplasty or Latanoprost. Int J Mol Sci. 2024;25(24):13464.
  25. Pillunat KR, Kretz FTA, Koinzer S, et al. Effectiveness and safety of VISULAS® green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation. Int Ophthalmol. 2023;43(9):2215-2224.

About Me

Dr. Suhail Sarwar. Best eye hospital in Lahore. Best Eye specialist in Lahore. Best eye clinic in Lahore. Best cataract surgeon in Lahore.

The proficient best eye specialist in Lahore.

Prof. Dr. Suhail Sarwar, an eminent cataract surgeon in Lahore and he is a famous eye specialist in Lahore because of his notable contributions to ophthalmic research. He has more than 30 years of experience in Mayo Hospital and King Edward Medical University that has the best eye hospital in Lahore, Pakistan. Now you people don’t need to go to all paranoia for getting your eye check-up done because we have found the best eye hospital in Lahore. This clinic assures that you get a top-quality treatment by providing you with the best eye doctor in Lahore.